Introduction
Drugs that are piperazine derivatives typically generate piperazine ring carbon alcohols or metabolize at the piperazine nitrogen to generate hydroxylamines/N-oxides as phase I metabolites and Nglucuronides or N-O-glucuronides as phase II metabolites (Delbressine et al., 1992; Kassahun et al., 1996; Schaber et al., 2001; Miller et al., 2004) . N-Glucuronides are common metabolic products of drugs containing amino groups or aromatic nitrogen heterocycles and in some cases tertiary, secondary, and primary amines form N-glucuronides from a drug and its phase I metabolites (Dalgaard and Larsen, 1999) . Porter et al. (1975) were the first to report the formation of quaternary ammonium-linked glucuronide from a tertiary amine in humans. The enzyme involved was later shown to be UGT1A4 (Green and Tephly, 1996) . In other cases with tetrazoles and triazoles, UGT1A6 (Huskey et al., 1994a,b) or UGT1A9 (Omura et al., 2007) was involved. In addition, N-glucuronides of pyridine (synthesis) (Dalgaard, 1983) ) and imidazoles (biosynthesis) (Vashishtha et al., 2002) ) are also known. It appears that liver microsomes from primates, guinea pigs, and rabbits form imidazole glucuronides more readily than microsomes from rats and dogs. N-Glucuronidation of tertiary piperazines resulting in quaternary structures seems to occur mainly in primates (Chiu and Huskey, 1998) . N ϩ -Glucuronidation as a metabolic pathway and the stability and spectroscopy of the glucuronides have been reviewed by Hawes (1998) . A convenient route of synthesis of quaternary ammonium glucuronides has recently been described previously (Iddon et al., 2010) . In some cases it can be a challenge to distinguish whether N-and O-glucuronidation has taken place, e.g., of a hydroxy isoxazole (Andersen et al., 1989) and requires more extensive investigation. The present study describes such a challenge. During investigation of the disposition of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide (Lu AA21004, 1) as a novel multimodal antidepressant agent under development for treatment of depression (Bang-Andersen et al., 2011) in humans, two major metabolites were observed in plasma and urine. The molecular weight and mass spectra of these metabolites indicate addition of oxygen and glucuronic acid to the piperazine ring of the parent drug. However, HPLC-MS data alone failed to provide sufficient evidence of the exact structures. The present study describes the identification of the two metabolites (2S,3S,4S,5R,6S)-6-{4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin-1-yloxy}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid (3) and 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-1-␤-Dglucuronic acid-piperazine 1-oxide (4) (Fig. 1 ) using a novel and unambiguous organic synthesis and biosynthetic approach, respec-tively. Biosynthesis was performed using UDPGA and human liver microsomes followed by semipreparative HPLC purification and successful application of NMR spectroscopy. A sufficient amount of 4 was obtained to run NMR experiments in the carbon-observe mode, resulting in NMR data that led to the unambiguous identification of the structure of 4.
Materials and Methods
Chemicals. 1, 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin-1-ol (2) and 3 were obtained from H. Lundbeck A/S (Copenhagen, Denmark). The purities of 1 and 2 were Ͼ99%. The purity of 3 was 81.6% (UV) and 100% (evaporative light scattering). HPLC-grade solvents were from Thermo Fisher Scientific (Waltham, MA) and Sigma-Aldrich (St. Louis, MO). Uridine 5Ј-diphosphoglucuronic acid trisodium salt, alamethicin, D-saccharic acid 1,4-lactone monohydrate, magnesium chloride, Tris-HCl, ␤-glucuronidase (type VII-A from Escherichia coli), ammonium acetate, deuterium oxide, and DMSO-d 6 were purchased from Sigma-Aldrich. Potassium dihydrogen phosphate, sodium hydroxide, acetic acid, hydrochloride acid (2 N), ammonium hydroxide solution (25% aqueous), potassium hydroxide, ammonium acetate, and formic acid were purchased from Merck (Darmstadt, Germany). Acetonitrile-d 3 was purchased from Cambridge Isotope Laboratories (Andover, MA).
Biological Preparations. Human liver microsomes, pool of mixed gender (20 mg protein/ml), was purchased from XenoTech, LLC (Lenexa, KS).
Preparative Scale Biosynthesis of N-Oxide/N-Glucuronide (4). Pooled human liver microsomes (mixed gender, final concentration, 0.5 mg of protein/ ml) were added to 100 ml of 100 mM Tris-HCl buffer, pH 7.4, containing 5 mM MgCl 2 , 2.5 mM UDPGA, 12.5 g/ml alamethicin, 5 mM D-saccharic acid 1,4-lactone, and 200 M hydroxyl amine 2. This suspension was incubated for 4 h at 37°C, and the reaction was stopped by the addition of ice-cold (Ϫ20°C) acetonitrile (100 ml). To obtain enough glucuronide metabolite 4 for further investigation, the biosynthesis was repeated four times. The ice-cold incubation suspension (200 ml) containing the glucuronide metabolite 4 was centrifuged (16,000g, 4°C, 10 min) and evaporated at 35°C under nitrogen in a TurboVap LV evaporator (Zymark Corp., Hopkinton, MA) until concentrated approximately 17-fold.
Semipreparative HPLC-MS Purification. The HPLC-MS system consisted of a G2258A dual-loop autosampler PS, a G1311A quaternary pump, a G1316A thermostatted column compartment, a G1364B fraction collector prep scale, and a G1956A LC/MSD Quad VL system (Agilent Technologies, Santa Clara, CA). The concentrate (approximately 12 ml from the biosynthesis) was diluted with 12 ml of mobile phase A and purified by five successive 5-ml injections on a XBridge C18 column (10 ϫ 250 mm; Waters, Milford, MA) eluted at 4 ml/min with a linear gradient applied (0 -20 min) from 70 to 40% mobile phase A (acetonitrile-water, 10:90, 0.05% formic acid) and 30 to 60% mobile phase B (acetonitrile-water, 90:10, 0.05% formic acid). Fractions containing the glucuronide metabolite 4 with m/z 491 (electrospray-positive) and retention time of approximately 11 min were collected and evaporated at 35°C under a stream of nitrogen. The final yield from the four incubations and subsequent HPLC purifications was approximately 10 mg of glucuronide metabolite 4 (yield 25%, needle-shaped crystalline material) from 25 mg of starting material 2 (see Fig. 10 ).
Analytical HPLC-MS. Ion trap. The HPLC-MS system consisted of a G1367 autosampler, a G1312A binary pump, a G1316A thermostatted column compartment, a G1322A degasser (Agilent Technologies), and an LQC Deca XP mass spectrometer (Thermo Fisher Scientific). Injections (10 l) were made on a Symmetry C18 column (2.1 ϫ 100 mm; Waters) eluted at 0.25 ml/min with a linear gradient applied (0 -25 min) from 100 to 50% mobile phase A (acetonitrile-50 mM ammonium acetate, pH 5.0, 20:80) and 0 to 50% mobile phase B (acetonitrile-50 mM ammonium acetate, pH 5.0, 80:20) followed by a washout (100% B, 5 min) and reequilibration (100% A, 6 min).
MicrOTOF. Accurate masses were obtained on an HPLC-MS system that consisted of a G1313A autosampler, a G1311A quaternary pump, a G1316A column oven, a G1322A degasser (Agilent Technologies) and a MicrOTOF system (Bruker Daltonics, Bremen, Germany) using an electrospray ionization or atmosphere pressure photoionization interface. Injections (5 l) were made on a SunFire C18 column (4.5 ϫ 50 mm, 3.5 m; Waters) eluted at 2.5 ml/min with a linear gradient applied (0 -2 min) from 95 to 0% mobile phase A (water ϩ 0.05% trifluoroacetic acid) and 5 to 100% mobile phase B (water-acetonitrile, 5:95, ϩ 0.03% trifluoroacetic acid) followed by washout (100% B, 0.5 min).
NMR Spectroscopy. NMR spectra were recorded at 11.75 or 14.10 T on Bruker Instruments (Fällanden, Switzerland). The instruments were an Avance I 500 equipped with a 5-mm four-nucleus probe ( Enzymatic Hydrolysis of N-O-glucuronide (3) and N-oxide/N-glucuronide (4). The glucuronide metabolites 3 and 4 (10 M) were each dissolved in 100 mM potassium dihydrogen phosphate buffer solution, pH 6.8, and added to a ␤-glucuronidase solution (E. coli, 1000 IU/ml). The suspensions were incubated at 37°C for 30 min for complete hydrolysis to mainly 2 and secondarily 1. Hydrolysis of 3 and 4 (10 M) spiked to human plasma required higher amounts of ␤-glucuronidase (up to 5000 IU/ml) and/or longer incubation times (up to 4 h).
Synthesis of N-O-Glucuronide (3): Experimental. {[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-(2-hydroxy-ethyl)-amino}-ethanol (6)
. Aniline (5) (2.75 g, 12.0 mmol) was dissolved in N-methylpyrrolidinone (20 ml), and then potassium iodide (4.13 g, 24.9 mmol) and ethyl bromoacetate (8.28 ml, 74.7 mmol) were added. The mixture was warmed to 120°C and stirred overnight (22 h). Additional ethyl bromoacetate (2 ml, 18 mmol) was added, and the mixture was stirred for an additional 4 h. The mixture was partitioned between water (100 ml) and tert-butylmethyl ether (100 ml), and the organic phase was washed with water (two 50-ml washes) and brine (50 ml). The combined aqueous phases were extracted with tert-butylmethyl ether (50 ml), and the combined organic phases were dried (Na 2 SO 4 ), filtered and evaporated to dryness in vacuo, affording a crude mixture of the corresponding diester, which was taken directly to the next step.
Lithium borohydride in THF (2 M, 50 ml) was added to the diester at 0°C, and the mixture was stirred overnight (18 h). Then, 2 M NaOH (150 ml) was added, and the mixture was stirred for 1ch and partitioned between water (100 ml) and CH 2 Cl 2 (150 ml). The aqueous phase was extracted with CH 2 Cl 2 (50 ml), and the combined organic phases were dried (Na 2 SO 4 ), filtered, and evaporated to dryness in vacuo, affording a slightly yellow oil. The residue was purified using silica gel column chromatography (AcOEt-heptane, 1:19 -1:1) affording diol {[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-(2-hydroxy-ethyl)-amino}-ethanol (6) (1.8 g, 46% over the two-step sequence) as a colorless oil. 
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(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-{4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin-1-yloxy}-tetrahydro-pyran-2-carboxylic acid methyl ester (11).
Oxalyl chloride in CH 2 Cl 2 (2 M, 3.54 ml) was added to CH 2 Cl 2 (10 ml) and cooled to Ϫ78°C, followed by the addition of DMSO (1.00 ml, 14.2 mmol), and the mixture was stirred for 15 min, and then diol 6 (900 mg, 2.835 mmol) in CH 2 Cl 2 (1.0 ml ϩ 0.5 ml rinse) was added dropwise. The mixture was stirred under nitrogen for 30 min, triethylamine (3.95 ml, 28.4 mmol) was added, and the mixture was slowly warmed to Ϫ20°C over 1 h. Then the cooling bath was removed, and the mixture was stirred for 5 min at room temperature. In a separate vial, MeOH (10 ml, 250 mmol) was added to (2S,3S,4S,5R,6S)-3,4,5-triacetoxy-6-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester (10) (990 mg, 2.0 mmol), followed by hydrazine monohydrate (1:1, hydrazine-water, 115.1 l). After 5 min, the mixture was transferred to the vial containing the above-described Swern oxidation mixture, followed by the addition of AcOH (5.8 ml) and sodium cyanoborohydride (0.75 g, 12 mmol), and the mixture was stirred for 2 h. The mixture was concentrated to half-volume, AcOH (6 ml) and sodium at ASPET Journals on July 3, 2017 dmd.aspetjournals.org cyanoborohydride (0.35g) were added, and the mixture was stirred at 45°C overnight (19 h). The mixture was partitioned between AcOEt (20 ml) and saturated aqueous NaHCO 3 (20 ml), and the organic phase was washed with saturated aqueous NaHCO 3 (two 10-ml washes). The combined aqueous phases were extracted with AcOEt (10 ml), and the combined organic phases were dried (Na 2 SO 4 ), filtered, and evaporated to dryness in vacuo. The residue was subjected to silica gel column chromatography (AcOEt-heptane, 1:9 -1:0)
affording an off-white foam (245 mg). The product was precipitated from diethyl ether (1 ml), and the white solid was a 2:1 mixture of by-product (from the phthalimide) and desired product, whereas the filtrate was an impure mixture of desired product 11, hydroxyl amine 2, and unknown phthalimide by-products. The filtrate was evaporated to dryness and subjected to silica gel column chromatography (MeOH-CH 2 Cl 2 , 1:99 -1:9), which removed the hydroxylamine 2 (200.3 mg, 31%), but not the other by-products. The residue was then subjected to FIG. 5. 1 H NMR spectrum of hydroxyl amine 2.
FIG. 6.
13
C NMR spectrum of hydroxyl amine 2.
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at ASPET Journals on July 3, 2017 dmd.aspetjournals.org preparative thin-layer chromatography (MeOH-CH 2 Cl 2 , 3:97), which removed the phthalimide by-product. Finally, the mixture was precipitated in diethyl ether (0.5 ml at Ϫ20°C), affording glucuronic methyl ester 11 (105 mg, yield ϭ 8.1%). Data for 2: 1 H NMR (CDCl 3 , 500 M Hz) 8.11 (s, 1H), 7.35 (s, 1H, J ϭ 7.5 Hz), 7.25 (s, 1H), 7.16 (d, 1H, J ϭ 7.5 Hz), 7.13-7.09 (m, 2H), 6.92 (t, 1H, J ϭ 7.5 Hz), 6.41 (d, 1H, J ϭ 7.5 Hz), 3.26 (d, 2H, J ϭ 10.5 Hz), 3.14 (d, 2H, J ϭ 10.5 Hz), 2.89 (t, 2H, J ϭ 11.0 Hz), 2.68 (t, 2H, J ϭ 9.5 Hz), 2.34 (s, 3H), 2.26 (s, 3H).
13 C NMR (CDCl 3 , 125 M Hz) 150.3, 143.4, 140.3, 137.4, 135.0, 133.4, 129.8, 129.0, 127.6, 127.4, 126.1, 121.9, 59.8, 51.8, 22.5, 21.8 169.5, 169.1, 167.3, 142.4, 139.3, 136.2, 134.7, 131.7, 127.8, 126.3, 125.5, 124.6, 119.9, 102.8, 72.5, 72.3, 69.7, 69.5, 52.9, 21.2, 20.7, 20.6, 20.5. HRMS: [M ϩ H] ϩ ϭ 631.2320; found 631.2321.
4-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-morpholin-2-one (7)
. Diol 6 (70.1 mg, 0.221 mmol) was dissolved in CH 2 Cl 2 (0.80 ml), DMSO (0.150 ml, 2.11 mmol) and N,N-diisopropylethylamine (115 l, 0.662 mmol) were added, and the reaction mixture was stirred at Ϫ10°C under nitrogen. Sulfur trioxide ⅐ pyridine (87.9 mg) was dissolved in DMSO (0.300 ml, 4.23 mmol) and added to the reaction mixture. The mixture was stirred for 30 min, while warmed to 0°C. The mixture was purified by directly pouring it onto a silica gel column (AcOEt-heptane, 1:4) affording the undesired lactone 7 (51 mg, 74%) as a colorless oil. Data for 7: 1 H NMR (CDCl 3 , 500 M Hz) 7.34 (d, 1H, J ϭ 8.0 Hz), 7.16 (s, 1H), 7.12 (t, 1H, J ϭ 7.5 Hz), 7.05-7.02 (m, 2H), 6.95 (t, 1H, J ϭ 8.0 Hz), 6.59 (d, 1H, J ϭ 8.0 Hz), 4.47 (t, 2H, J ϭ 4.5 Hz), 4.00 (s, 2H) 3.36 (t, 2H, J ϭ 4.5 Hz), 2.37 (impurity), 2.31 (impurity).
13 C NMR (CDCl 3 , 125 M Hz) 167.5, 145.6, 142.3, 139.5, 136.0, 134.8, 131.9, 128.0, 126.9, 125.8, 125.7, 119.8, 68.9, 53.6, 48.5 .
N-O-Glucuronide 3. The tetra acetate 11 (84.1 mg, 0.133 mmol) was dissolved in MeOH (3.0 ml, 74 mmol), 5.4 M sodium methoxide in MeOH (24.69 l) was added, and the reaction mixture was stirred under nitrogen for 1 h. Then Amberlyst 15 (approximately 10 beads) was added, and the mixture was concentrated and purified directly using silica gel column chromatography (MeOH-CH 2 Cl 2 , 2:98 -10:90), affording the corresponding methyl ester (52 mg, 77%). The methyl ester (25 mg, 0.050 mmol) was dissolved in acetone (2.5 ml, 34 mmol), 1.0 M sodium hydroxide in water (0.248 ml) was added, resulting in a white precipitate (presumably the sodium salt), and the reaction mixture was stirred for 5 min. Subsequently, the solvent was decanted off. The residue was dissolved in MeOH-DMSO-H 2 O (1:1:4) and filtered. The clear solution was subjected to preparative HPLC, affording N-O-glucuronide 3 (13.2 mg, 54%, solid) (Fig. 2) .
Results
Dosing of humans orally with 1 afforded a number of metabolites in plasma and urine, including two compounds verified to be 3 and 4, both with (M ϩ H) ϩ ϭ m/z 491 using HPLC-MS (Fig. 3) . Fragmentation of the m/z 491 ions in the ion trap mass spectrometer resulted in the MS 2 spectra shown in Fig. 4 . The ions at m/z 315, 299, 298, and 240 for 4 and 299, 298, 256, and 240 for 3 correspond to the loss of a glucuronic acid moiety (m/z 315), loss of a glucuronic acid moiety and oxygen (m/z 299), and loss of an O-glucuronic acid moiety and fragmentation of the piperazine ring (m/z 240 and 256). This pattern is consistent with the fragmentation of glucuronic acid conjugate metabolites of a monooxygenated piperazine derivative (Delbressine et al., 1992; Schaber et al., 2001; Miller et al., 2004) . Analysis of the (bio)synthesized standards containing 3 and 4 using MicrOTOF MS showed the compounds to have exact mass values of 491.18608 and 491.18325, respectively. The observed values are within 2.9 and 2.8 ppm (for 3 and 4, respectively) of a theoretical exact mass of C 24 H 31 N 2 O 7 S, corresponding to a monooxygenated glucuronide metabolite of 1. Analysis of the starting material 2, the hydroxylamine, for the biosynthesis of 4, shows the compound to have an exact mass value of 315.15177. The observed value is within 2.5 ppm of the (Figs. 5 and 6) .
Metabolite 3 was unambiguously prepared using a novel organic synthesis, and various NMR experiments were performed for structural identification purposes. See Tables 1 and 2 for chemical shift  values and Figs. 7 and 8 for 1 H and 13 C NMR spectra. Treatment of 3 and 4 with ␤-glucuronidase resulted in hydrolysis mainly to a compound with (M ϩ H) ϩ ϭ m/z 315 and to a lesser extent to a compound with (M ϩ H) ϩ ϭ m/z 299. The retention times and MS spectra were consistent with those obtained for the hydroxyl amine 2 and the parent drug 1.
Organic synthesis of 4 was unsuccessful, but in vitro biosynthesis using human liver microsomes, UDPGA, alamethicin (antibiotic, precautionary measure) and saccharic acid lactone (␤-glucuronidase inhibitor, precautionary measure) (Miller et al., 2004; Picard et al., 2005; Bowalgaha et al., 2007; Wen et al., 2007a,b; Hintikka et al., 2008) and subsequent semipreparative HPLC-MS resulted in the production of approximately 10 mg of the metabolite 4. During evaporation of the fractions collected during semipreparative HPLC-MS, 4 started precipitating and was collected in sufficiently pure form for one-and two-dimensional NMR experiments. The isolated metabolite was confirmed to be identical to the metabolite (M ϩ H) ϩ ϭ 491 observed in various in vitro and in vivo samples, including human urine, based on identical retention times and MS fragmentation pattern (Figs. 9 and 10) .
The structure of 4, including assignment of all protons, was determined using a combination of one-dimensional ( 1 H, decoupled 13 C) and two-dimensional techniques (TOCSY) (Bax and Davis, 1985) for 1 H-1 H correlations in coupling networks, gradient selected HSQC (Kay et al., 1992; Willker et al., 1993 ) for direct correlations between 1 H and 13 C, gradient selected HMBC (Bax and Davis, 1985; Willker et al., 1993; Cicero et al., 2001 ) for long-range correlations between 1 H and 13 C, and ROESY (Bax and Davis, 1985; Hwang and Shaka, 1992) for correlating protons close in space). See 1 H and 13 C NMR spectra in Figs. 11 and 12 . The anomeric proton of the glucuronic acid moiety was observed at 4.93 ppm and with a coupling constant of J H-1Ј, H-2Ј of 6.6 Hz. See Tables 1 and 2 
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The exact mass data obtained for 3 and 4 (corresponding to C 24 H 31 N 2 O 7 S), and their fragmentation patterns are consistent with monooxygenated glucuronide metabolites of the piperazine 1 (Delbressine et al., 1992; Schaber et al., 2001; and Miller et al., 2004) .
The anomeric protons of 3 and 4 were observed at 4.57 and 4.93 ppm and with coupling constants J H-1Ј, H-2Ј of 8.5 and 6.6 Hz, respectively. Chemical shifts and coupling constants of tertiary N-glucuronides and ␤-anomers are found at 5.33 to 6.31 ppm and 8.3 to 9.5 Hz, respectively (Andersen et al., 1989; Keating et al., 2006; Nakazawa et al., 2006; Yan et al., 2006) , which are at lower field (higher parts per million) than the anomeric proton of N-O-glucuronides (range of chemical shift 4.54 -4.84 ppm and coupling constants of 8.4 -9 Hz) (Straub et al., 1988; Delbressine et al., 1992; Turgeon et al., 1992; Schaber et al., 2001; and Miller et al., 2004) . The N-Oglucuronide 3 fits the published range. For quaternary N-glucuronides chemical shift values for the anomeric protons of 4.39 to 4.6 ppm with coupling constants of approximately 9 Hz have been reported (BreyerPfaff et al., 1990; Kaku et al., 2004) . The proposed N-oxide/Nglucuronide 4 does not completely fit any of the ranges. The final evidence for the proposed structure can be found in the distance correlations observed in the ROESY spectra (Hwang and Shaka, 1992) The lower graph in each spectrum shows the intensity of the distance correlations between the anomeric proton and the protons close in space. For 3, the correlation peaks of H-1Ј (4.57 ppm), H-3Ј FIG. 8. 13 C NMR spectrum of N-O-glucuronide metabolite 3.
FIG. 9. Biosynthesis of 4, incubating 2 (200 M)
with human liver microsomes (0.5 mg of protein/ ml) and UDPGA (2.5 mM) at 37°C for 4 h.
(3.22 ppm), and H-5Ј (3.65 ppm) in the glucuronide moiety are equivalent in size, whereas a weaker correlation is seen to H-2Ј. As expected, no correlations to the piperazine protons are observed for the anomeric proton in 3. However, for 4, apart from the expected correlations between H-1Ј (4.93 ppm), H-3Ј (3.44 ppm), and H-5Ј (4.02 ppm) of the glucuronide moiety, an additional distance correlation is observed between H-1Ј and the axial piperazine proton H-3Љax (3.68 ppm). This latter correlation shows that the glucuronide and piperazine moieties have a spatial distance that can only be explained by the structure shown in Fig. 11 . The N-oxide/N-glucuronide metabolite 4 represents a new class of quaternary N ϩ -glucuronides. It should be taken into account in future studies of conjugated hydroxylamines that unsymmetrically substituted amines will afford diastereomeric conjugates.
There is also indirect evidence for the structure of 4 based on different theoretical structures. In particular, differentiating between 3 and 4 was deemed difficult; therefore, a structurally unambiguous synthesis of 3 was developed. The strategy was to incorporate the N-O-hydroxylamine moiety as early as possible from starting materials known from the published literature. Therefore, phthalimide (10) was chosen as the starting material (Mitchell and Whitcombe, 2000) . The phthalimide hydroxylamine-protecting group was removed via brief exposure to hydrazine in MeOH and immediately transferred to the next reaction because of its inherent instability under the reaction conditions. The free hydroxylamine 9 was coupled with dialdehyde 8, using sodium cyanoborohydride, thereby affording 11 via a double reductive amination. The major product of the reaction was the hydroxylamine 2, which was used in the biosynthesis of 4. Several conditions were screened to oxidize diol 6 to the corresponding dialdehyde 8. Surprisingly, when the oxidation was attempted using Parikh-Doering conditions (i.e., SO 3 ⅐ pyridine, DMSO, and N,Ndiisopropylethylamine) (Parikh and Doering, 1967) , lactone 7 was afforded instead of the desired dialdehyde 8. This problem was overcome by using a Swern oxidation (Tidwell, 1990) . One could possibly envision epimerization at the anomeric position under the slightly acidic conditions during the reductive amination, but because 
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One could speculate that 4 might be a "3 carboxylic ester alternative." In this case, the carboxylic moiety of the glucuronic acid would be linked to the N-hydroxylamine moiety. A distance correlation would not have been observed between the anomeric proton of the glucuronide and the piperazine ring protons in this structure. However, a correlation is observed and the structure can thus be rejected.
A second alternative structure could theoretically have been the ␣-anomer of 3. However, in this case the coupling constant of the anomeric proton in the glucuronide moiety would be only 2 to 3 Hz (Smith and Benet, 1986) , and the actual observed coupling constant is 
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at ASPET Journals on July 3, 2017 dmd.aspetjournals.org 7 to 8 Hz, indicative of the ␤-anomer, together with the fact that strong distance correlations from H-1Ј to H-3Ј and H-5Ј are seen.
A third alternative structure is the N-1 piperazine glucuronide instead of the observed N-4 substituted version. If this were the case, the resulting quaternary N would result in a downfield shift of adjacent carbons of the piperazine ring (Miller et al., 2004) . This is not seen. In addition, distance correlations between the glucuronide protons (anomeric proton), piperazine protons H-2Љ and/or H-6Љ, and an adjacent aromatic ring would have been observed if 4 had an N-1 glucuronide structure. None of this was observed.
The last speculated alternative structure is the N-1 oxide N-4 glucuronide, but the shift considerations of the third alternative also apply here.
During the biosynthesis, 1 was observed in the reaction mixture, suggesting that either the substrate 2 or one of the products 3 or 4 is hydrolyzed to give 1. It is most likely to arise from the nonenzymatic hydrolysis of either the N-O bond in the glucuronide metabolite 3 or the C-O bond in 2 in the reaction mixture (pH 6.8) or during the acidic HPLC-MS conditions (Turgeon et al., 1992; Yan et al., 2006) . Enzymatic and chemical hydrolysis of quaternary ammonium-linked glucuronide metabolites, such as 4, is generally reported to be mediated only by E. coli (pH 6.5-7.4) and nonenzymatically only at extreme pH (Kowalczyk et al., 2000) , in line with the suggestion above that the parent compound 1 originates from hydrolysis of 2 or 3.
In conclusion, it is worth noting that during the analysis of samples from humans dosed with 1 and from the biosynthesis previously described, both the N-O-glucuronide 3 and the N-oxide/N-glucuronide 4 were formed. Furthermore, the N-oxide/N-glucuronide 4 is a new class of metabolite that will possibly be observed in future metabolism studies of other drugs.
